Oncologist in Kolkata

Dr Animesh Saha

MBBS, MD(Radiation Oncology), DNB(Radiation Oncology), MNAMS, PDCR, FRCR(London), CESR(UK), PGCME- Oncology (University of Dundee). Ex- Consultant Leeds Cancer Center, UK

Work Experience

11 yrs+

Registration No

WBMC - 64647

Language

English, বাংলা, हिंदी

Location

Apollo Multispecialty Hospitals
  • Dr Animesh Saha is a qualified Clinical Oncologist with vast experience. He is currently working as a full time Consultant at Apollo Gleneagles Hospital, Kolkata. Lately, He was working as a Consultant Clinical Oncologist (Sub specialty- Lung and Hepatobiliary cancers) in Leeds Cancer Centre, UK since November 2018. Prior to that, He was doing an International training fellowship in Clinical Oncology in the same Institute in UK from March 2017. Prior to that, He did his fellowship in Clinical Oncology from Tata Medical Centre, Kolkata from June 2013 to January 2017. He passed FRCR clinical Oncology exam in April 2018. He completed his MD Radiotherapy (From IPGME&R and SSKM hospital, Kolkata) in 2013 and DNB in 2014 in Radiation Oncology. He passed MBBS from R.G.Kar Medical College & Hospital, Kolkata back in 2008. He has keen interest in Lung, GI, Head & neck cancers and adult CNS tumors. He does Radiotherapy, systemic therapy (Chemotherapy, Immunotherapy, Targeted therapy), Palliative/ supportive care for these sub sites. He has extensive expertise in Lung and Liver SBRT. He has keen in interest in clinical research and hoping to set up collaborative research with UK.

 

 


Speciality And Areas Of Interest

  • Lung cancer, Mesothelioma, Thymoma, Head & neck cancer, GI cancers (Esophageal cancer, Stomach Cancer, Liver cancer, Gall bladder cancer, Pancreas cancer, Cholangiocarcinoma, Small bowel cancer, Colon Cancer, Rectal cancer, Anal canal cancer),Adult CNS tumor (Brain & Spine tumor).
  • Urology cancer ( Bladder, Prostate, Kidney cancer).

Work Experience

  • Consultant Clinical Oncologist Apollo Gleneagles Hospitals, Kolkata from Nov 2019 Till now
  • Consultant Clinical Oncologist Leeds Cancer Centre, UK, NHS trust from Nov 2018- Nov 2019
  • Specialist registrar Leeds Cancer Centre, UK, NHS trust from March 2017 Nov 2018
  • Clinical Oncology Fellow Tata Medical Center, Kolkata June 2013 to Jan 2017
  • Post Graduate trainee IPGME&R and SSKM hospital, Kolkata June 2010 to June 2013

Awards and Achievements

  • Certificate of Eligibility for Specialist Registration (CESR), UK awarded by General Medical Council, UK in October 2019.
  • He received Cyclotron Trust Award with travel grant to attend the Education Sessions of PTCOG-58 conference held in Manchester, United Kingdom between 10-15June,2019.
  • He was selected for ESMO preceptorship on Head & neck cancer which was held in  Zurich, Switzerland between,May,2019
  • Having qualified for the award of Diplomate of the National Board of Examinations in Radiotherapy at the examination held in December, 2013; He has been  admitted by the council as member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018
  • International training fellowship in St James University Hospital (Leeds teaching hospital), UK from March 2017- October 2018.
  • Fellowship in Clinical oncology from Tata Medical Center, Kolkata, India from June, 2013 to January, 2017.
  • He was selected for ESMO preceptorship on Brain tumor held between September 28, 2018-September 29, 2018 in Athens, Greece.
  • FRCR in Clinical Oncology awarded by Royal College of Radiologists in April,2018
  • Hypo-fractionated radiotherapy schedule of 35Gy in 10 Fractions in advanced incurable breast cancer: a prospective Phase I/II study (HYPORT study). He got first prize for poster presentation in controversies in Clinical Oncology, which was held in Kolkata, India in 2016.
  • He had an oral presentation in The Royal College of Radiologists proffered paper session in NCRI conference 2015, Liverpool, UK; for which He got ‘The Company of Biologists Travel Award’
  • ‘Is daily MVCT imaging really required in helical tomotherapy for head and neck cancers? : An analysis of a large dataset of 2858 fractions’. He had presented this research work in AROICON West Bengal chapter 2013 in Kolkata,India.

 

Research and Publications

Dr Saha has participated as a sub investigator in many international trials. Some of the trials are-

  • A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
  • Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers (ABC07 trial)
  • A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases (CORE trial)
  • ETOP/IFCT 4-12 STIMULI trial which is an Open-label, randomised, two-arm, phase II trial looking into addition of Immunotherapy with Nivolumab and Ipilumumab to standard of care  in limited stage Small cell lung carcinoma.
  • A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
  • GO40241 Phase III randomized, double-blind, placebo-controlled study (Neoadjuvant early stage resectable NSCLC) –Impower030 trial.
  • Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer: A randomised phase III trial (SARON study)
  • A multi-centre randomised study of induction chemotherapy followed by capecitabine(+/-nelfinavir) with high or standard dose radiotherapy for locally advanced nonmetastatic pancreatic cancer (SCALOP 2 study)
  • A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma. (SYSTEM 2 trial).
  • A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).
  • A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006).
  • Adjuvant Durvalumab/placebo following SABR for stage I/II medically inoperable NSCLC (PACIFIC 4 study).
  • Adjuvant Durvalumab following sequential chemotherapy and radiotherapy in patients with unresecatble stage III NSCLC (PACIFIC 6 study).

Dr Saha has numerous publications in national and international peer reviewed journals. Some of his publications include-

  • Can Dosimetry Affect Overall Survival in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer Treated with Stereotactic Ablative Radiotherapy (SABR)? An Analysis of 1300 Patients. 
  • Setting up a lung Stereotactic Body Radiotherapy (SBRT) service in a tertiary centre in eastern India– The process, quality assurance and early experience. 
  • Radical radiotherapy or chemoradiotherapy for inoperable locally advanced non-small-cell lung cancer (NSCLC) - Analysis of patient profile, treatment approaches and outcomes of 213 patients at a tertiary cancer centre. 
  • A Prospective Study of an Offline Matching Protocol for Head and Neck Cancer on Helical Tomotherapy: The F5 Study.
  • Acute toxicity and in-vivo dosimetry of a two week hypofractionated schedule within the HYPORT study. 
  • High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
  • Quality Assurance and Acute Toxicities of a 2 Week Hypofractionated Palliative Radiotherapy Schedule used in a Prospective Phase I/II Study (HYPORT Study).
  •  Evaluating the Need for Daily Image Guidance in Head and Neck Cancers Treated with Helical Tomotherapy: A Retrospective Analysis of Large Number of Daily Imaging-based Corrections. Clin Oncol, 2016.
  • Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators? 
  • Helical tomotherapy based intensity modulated radiotherapy for the management of difficult clinical situations in breast cancer.
  •  A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.

Professional Memberships and Certifications

Certification

  • Certificate of Eligibility for Specialist Registration (CESR), UK awarded by General Medical Council, UK in October 2019.
  • Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018.
  • FRCR in Clinical Oncology, Awarding body Royal College of Radiologists, April 2018.
  • Professional diploma in clinical research awarded by Catalyst Clinical Services Pvt. Ltd, India, August,2014.
  • DNB Radiotherapy awarded by National Board of Examinations, India in June,2014
  • MD Radiotherapy awarded by The West Bengal University of Health Sciences in April 2014.
  • M.B.B.S awarded by The West Bengal University of Health Sciences in November,2009

Professional Memberships

  • Indian medical association (life member no- BGL/9348/119/305/161892/2011-12/L)
  • Association of radiation oncologists of India ( life member no- 1672)
  • European society of medical oncology (ESMO ID- 81560).
  • Royal College of Radiologists (Membership no: 315972)
  • European Society for Radiotherapy and Oncology (Membership no-24697)
  • Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018.
Timing SUN- SAT (12:00 PM-12:01 PM)
Book Appointment
Need Help? 1860 500 1066